STO · NANEXA.ST
Nanexa AB (publ)
SEK 10.32+SEK 0.14 (+1.38%)
Nanexa AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 33.42% below the high.
Loading market information…
STO · ALZCUR.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
AlzeCure Pharma AB’s quoted price sits in the upper half of its reported 52-week range, 25.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
AlzeCure Pharma AB’s next earnings report is currently expected on Nov 11, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow AlzeCure Pharma AB’s reporting calendar.
THE COMPANY BEHIND THE TICKER
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. The company was founded in 2012 and is based in Huddinge, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:44 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 10.32+SEK 0.14 (+1.38%)
Nanexa AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 33.42% below the high.
SEK 15.50-SEK 0.50 (-3.13%)
Mentice AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 18.21% below the high.
SEK 2.12+SEK 0.07 (+3.41%)
IRLAB Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 23.74% below the high.
SEK 14.35+SEK 0.10 (+0.7%)
Lipum AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 28.07% below the high.
SEK 12.60-SEK 0.30 (-2.33%)
Physitrack PLC’s quoted price sits in the upper half of its reported 52-week range, 22.94% below the high.
SEK 0.52+SEK 0.01 (+1.37%)
Klaria Pharma Holding AB (publ.)’s quoted price sits in the lower half of its reported 52-week range, 60.98% below the high.
SEK 0.40-SEK 0.01 (-2.69%)
AcuCort AB’s quoted price sits in the lower half of its reported 52-week range, 58.11% below the high.
SEK 0.24+SEK 0.01 (+2.13%)
KDventures AB’s quoted price sits in the lower half of its reported 52-week range, 82.14% below the high.
